Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.
Epistemonikos ID: 6824ffab2a67c8832ddb0ea1718da4018a7d517b
First added on: May 04, 2024